Urogen Pharma Ltd
URGN20.620USD
+0.150+0.73%
Fechamento 11/03, 16:00（ET）Cotações atrasadas em 15 min
952.63MValor de mercado
PerdaP/L TTM
Mais detalhes de Urogen Pharma Ltd Empresa
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Informações de Urogen Pharma Ltd
Código da empresaURGN
Nome da EmpresaUrogen Pharma Ltd
Data de listagemMay 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Número de funcionários235
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
Endereço9 Ha'ta'asiya St
CidadeRA'ANANA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIsrael
Código postal4365007
Telefone97297707601
Sitehttps://www.urogen.com/
Código da empresaURGN
Data de listagemMay 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Executivos da empresa Urogen Pharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Jelmyto
24.21M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Jelmyto
24.21M
0.00%
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
Outro
68.76%
Investidores
Investidores
Proporção
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
Outro
68.76%
Tipos de investidores
Investidores
Proporção
Hedge Fund
29.41%
Research Firm
21.32%
Investment Advisor/Hedge Fund
20.22%
Investment Advisor
17.19%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.10%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
309
45.30M
97.92%
-6.91M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RTW Investments L.P.
4.54M
9.82%
+709.10K
+18.49%
Jun 30, 2025
TD Securities, Inc.
3.19M
6.9%
+1.44M
+82.40%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.33M
5.04%
+2.33M
--
Aug 05, 2025
Jefferies LLC
2.20M
4.75%
+1.38M
+169.90%
Jun 30, 2025
Soleus Capital Management, L.P.
2.19M
4.72%
+2.19M
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.11M
4.56%
-34.56K
-1.61%
Jun 30, 2025
SilverArc Capital Management, LLC
2.02M
4.37%
+641.32K
+46.43%
Jun 30, 2025
Pontifax Venture Capital
1.49M
3.21%
-1.00
-0.00%
Mar 14, 2024
Morgan Stanley & Co. LLC
1.47M
3.19%
+1.27M
+633.13%
Jun 30, 2025
Arkin Communication, Ltd.
1.37M
2.96%
--
--
Feb 22, 2024
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
ARK Israel Innovative Technology ETF
2.13%
Tema Oncology ETF
1.43%
ALPS Medical Breakthroughs ETF
0.55%
Hypatia Women CEO ETF
0.19%
iShares Micro-Cap ETF
0.16%
Vanguard US Momentum Factor ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
Ver Mais
ARK Israel Innovative Technology ETF
Proporção2.13%
Tema Oncology ETF
Proporção1.43%
ALPS Medical Breakthroughs ETF
Proporção0.55%
Hypatia Women CEO ETF
Proporção0.19%
iShares Micro-Cap ETF
Proporção0.16%
Vanguard US Momentum Factor ETF
Proporção0.11%
ProShares Ultra Nasdaq Biotechnology
Proporção0.1%
Invesco Nasdaq Biotechnology ETF
Proporção0.1%
iShares Biotechnology ETF
Proporção0.07%
Fidelity Enhanced Small Cap ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
